First Page | Document Content | |
---|---|---|
![]() Medical statistics Lixivaptan Electrolyte disturbances Organochlorides Design of experiments Hyponatremia Clinical trial Vasopressin receptor antagonist Tolvaptan Medicine Health Epidemiology | Add to Reading List |
![]() | FDA Briefing Document for the Cardiovascular and Renal Drugs Advisory (CRDAC) Meeting Date: 13 September 2012DocID: EgJl - View Document |
![]() | Cardiokine Biopharma, LLC Lixivaptan Briefing Document NDA 203,009 Page 1 of 61DocID: DdpY - View Document |
![]() | The Targeting Acute Congestion with Tolvaptan In Congestive Heart Failure Study TACTICS-HF Felker GM, Adams KF, Cole RT, Patel CB, Egnaczyk G, Mentz RJ, Fiuzat M, and O’Connor CM on behalf of the TACTICS InvestigatorsDocID: tk1g - View Document |
![]() | ANNEX I SUMMARY OF PRODUCT CHARACTERISTICSDocID: 3jWY - View Document |